Kelun-Biotech

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.

News

Kelun-Biotech first to bag TROP2 approval in lung cancer

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

News

Kelun's MSD-partnered TROP2 drug gets first okay in China

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

Merck puts big bucks behind ADC alliance with China's Kelun

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech tha

MSD's Sac-TMT delivers in first phase 3 readout

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech first to bag TROP2 approval in lung cancer

Kelun's MSD-partnered TROP2 drug gets first okay in China

Merck puts big bucks behind ADC alliance with China's Kelun

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Kelun-Biotech

Editor's Picks